Lifeboat Foundation

Tell the FDA to identify and punish organisations who have broken US law by not reporting clinical trial results.

The US’s Food and Drug Administration has at last published its plan to identify and punish the organisations and people who have broken the law by not reporting clinical trial results. The FDA now wants to hear what we think about the plan.

The FDA Amendment Act 2007 says that lots of clinical trials in the US should be registered on ClinicalTrials.gov and report results information there within 12 months of the end of the trial. AllTrials’s FDAAA TrialsTracker shows that 628 clinical trials have broken this law since the first trials became due in January this year. We have written to the FDA every week to update them on the trials that have breached the law and shared with them a rolling estimation of the amount in fines the Agency could levy on the law breakers. The FDA has the power to fine people up to $10,000 a day and we have assessed that they could have raised $904,499,127 – nearly a billion dollars – but no one has ever been fined. That the FDA is now seriously considering how to start doing this is a long-awaited step forward.

Continue reading “Tell the FDA to identify and punish law breakers” »

Thoughts on the Eurosymposium on Healthy Ageing held by Heales in Brussels.

When I first learned about the possibility of achieving human rejuvenation through biotechnological means, little did I know that this would lead me to meet many of the central figures in the field during a conference some seven years later—let alone that I would be speaking at the very same event. Yet, I’ve had the privilege to attend the Fourth Eurosymposium on Healthy Ageing (EHA) held in Brussels on November 8–10, an experience that gave me a feel of just how real the prospect of human rejuvenation is.

A friendly, welcoming environment

Continue reading “Thoughts on the 2018 Eurosymposium on Healthy Ageing” »

LEXINGTON, Ky. (NOVEMBER 15, 2018) – Space Tango, a leader in the commercialization of space through R&D, bioengineering and manufacturing in microgravity, today announced ST-42, a fully autonomous robotic orbital platform designed specifically for scalable manufacturing in space. Launching in the mid 2020’s, ST-42 aims to harness the unique environment of microgravity to produce high value products across industries; from patient therapeutics to advanced technology products that have the potential to revolutionize industries here on Earth. ST-42 is an extension of the International Space Station’s (ISS) capabilities, and NASA’s creation of a robust commercial marketplace in low Earth orbit (LEO).

ST-42 will bring the economics of production in orbit into reality coupling autonomy with the reduced cost and larger number of launch vehicle providers. Space Tango expects the platform to be at the forefront of new breakthroughs in knowledge discovery, therapeutic solutions and manufacturing, and to provide the required capabilities for creation of new biomedical and technology product sectors in the commercial Space economy.

Continue reading “Unveils ST-42 for Scalable Manufacturing in Space for Earth-Based Applications” »

A new study takes a look at the relationship between metabolism, aging, and type 2 diabetes and in particular the mTORC1 protein complex, part of the mTOR pathway.

The mTOR pathway

The mechanistic target of rapamycin (mTOR) pathway is a major part of metabolism and is one of four major pathways that control it; collectively, the four pathways are part of deregulated nutrient sensing, which is one of the aging processes.

Continue reading “Too much mTOR is Linked to Diabetes and Aging” »

Research led by the University of Bristol has begun to unpick an important mechanism of antibiotic resistance and suggest approaches to block this resistance.

Antibiotic resistance is the ability of bacteria to defend against antibiotic attack, and the spread of these resistance mechanisms amongst bacteria is a global public health concern. A form of resistance caused by a family of bacterial proteins, the Verona Imipenemase (VIM) beta-lactamases, is of acute clinical concern because it can inactivate antibiotics (penicillins and related agents) that comprise over half of the global antibacterial market.

A team of researchers led by the University of Bristol have uncovered near-atomic level structural detail of VIM proteins. The research is published today [Thursday 15 November] in The FEBS Journal.

Continue reading “Scouting out bacterial defences to find new ways to counter-attack antibiotic resistance” »

A man in his 50s is the first of seven patients to receive the experimental therapy.

• By David Cyranoski, Nature magazine on November 15, 2018

Practices to enable more-thorough, earlier analyses of failed developments should be adapted to treatments for other challenging diseases, and should be part of regulators’ responsibilities. This will ensure that clinical research evaluates treatments faster and with more certainty.

Access to evidence from disappointing drug-development programmes advances the whole scientific process, explain Enrica Alteri and Lorenzo Guizzaro.

It’s imperative that Humanity understands the reality of warfare in these times when advanced and secret technologies are used against us on a daily basis.

From WiFi and cell phone frequencies to televisions and microwave ovens on up to the most exotic sonic weapons—it’s all disruptive and even lethal to the Human body and mind.

Because these weapons are silent and invisible, the war-loving aspects of society have been able to experiment with these methods for decades but the time for secrecy and these covert attacks on the life on our planet has come to an end.

Continue reading “Twenty-First Century Warfare: Secret and Silent Frequency Wars” »

After successfully transplanting the first 3D-printed cornea in an animal, North Carolina company Precise Bio has recently announced the launch of a dedicated business for creating marketable, 3D-printed products for human eyes. Founded by scientists from the Wake Forest Institute of Regenerative Medicine, this company is developing bio-fabrication printers that can restore cells, tissues, and organs. Their proprietary technology, a 4D bio-printing platform, is said to resolve existing limitations presented by other bioprinters to enable more complex tissues to be engineered for transplants and treatments. By focusing on developing marketable products for the eye, the company aims to achieve rapid advancement in its field and move to overhaul the whole organ transplant system.

When a cornea is damaged by disease or injury, a replacement is often needed to restore vision. Transplant surgery using donated corneas is an available solution, however, it relies on a deceased donor. While the waiting list in the United States is nearly non-existent, other countries require longer wait times, some over a year, before one is available. The Eye Bank Association of America estimates that around 10 million people suffer from corneal blindness that could potentially be restored via transplant surgery. An artificially manufactured cornea would overcome supply limitations while also contributing to the knowledge base to develop more complex organs such as hearts and livers.